• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Gemcitabine with ramucirumab improved overall survival for malignant pleural mesothelioma

byJamie ParkandSze Wah Samuel Chan
October 3, 2021
in Chronic Disease, Oncology, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Compared to the gemcitabine with placebo group, the gemcitabine with ramucirumab group had longer overall survival as a potential second-line treatment for malignant pleural mesothelioma.

2. Commonly experienced treatment-related side effects were neutropenia, hypertension, thromboembolism and fatigue.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Malignant pleural mesothelioma is the most common type of mesothelioma cancer and is often treated with chemotherapy. Currently, platinum compounds with pemetrexed is the first line standard of care treatment. However, there is limited information available on the standard of care as second-line treatment. This study aimed to evaluate the efficacy and safety of gemcitabine with ramucirumab in those with malignant pleural mesothelioma that has progressed during or after the first line standard of care treatment (platinum compounds with pemetrexed). The overall survival rate with the ramucirumab group was higher than the placebo group. There were no treatment related deaths in either group and the most frequent grade 3-4 treatment related side effects reported were neutropenia, hypertension, and fatigue. Thromboembolism was more common in the ramucirumab group. Limitations include the challenges of generalization to different ethnic patient populations, small sample size, and lack of head-to-head comparison with other available second-line treatments. Overall, this study demonstrated that gemcitabine with ramucirumab could be a potential second line treatment for malignant pleural mesothelioma to help improve overall survival.

Click to read the study in The Lancet Oncology

Relevant Reading: Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma

RELATED REPORTS

#VisualAbstract: Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma

#VisualAbstract: Pembrolizumab and chemotherapy combination improves survival in advanced pleural mesothelioma

Pembrolizumab and chemotherapy combination improves survival in advanced pleural mesothelioma

In-Depth [randomized controlled trial]: This was a phase 2, randomized, double-blind, placebo-controlled trial of 165 patients at 26 hospitals in Italy. Eligible patients included those who are age 18 and above, have documented disease progression despite receiving first line chemotherapy (pemetrexed + platinum compound) and have an Eastern Cooperative Oncology Group (ECOG) performance score of 0-2. Patients were excluded if they were taking anticoagulants, had uncontrolled hypertension, and had taken medications that target the VEGF signally pathway. Patients were randomized to receive either gemcitabine with placebo or gemcitabine with ramucirumab. The primary endpoint was the overall survival, starting from the date of randomization to the date of death. 161 patients (81: placebo group, 80: treatment group) were included in the analysis, as per the modified intention-to-treat protocol (patients were included in the analysis if they were placed in the correct randomized group and received their corresponding group’s treatment). The overall survival was longer in the ramucirumab group compared to the placebo group (hazard ratio [HR]: 0.71, 70% confidence interval [CI]: 0.59-0.85; p=0.028) with a longer median overall survival (treatment: 13.8 months, 70% CI: 12.8-14.4; placebo: 7.5 months, 70% CI 6.9-8.9). 44% of the ramucirumab group and 30% in the placebo reported grade 3-4 treatment related side effects. The most frequently reported ones were neutropenia (20% in ramucirumab group vs. 12% in placebo group), hypertension (6% vs. none), and fatigue (5% vs. 4%). Thromboembolism was also reported in 4% of the ramucirumab group versus 2% in the placebo group.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: malignant pleural mesotheliomaMesothelioma
Previous Post

Sleep quality during pregnancy may help predict emotional distress in postpartum period

Next Post

Active monitoring compared to maintenance capecitabine is a viable alternative for stable metastatic colorectal cancer

RelatedReports

#VisualAbstract: A Mobile Instant Messaging–Delivered Psychoeducational Intervention for Cancer Caregivers
StudyGraphics

#VisualAbstract: Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma

March 14, 2024
#VisualAbstract: Ubrogepant is safe and effective for acute treatment of migraine prodrome
StudyGraphics

#VisualAbstract: Pembrolizumab and chemotherapy combination improves survival in advanced pleural mesothelioma

January 26, 2024
Quick Take: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial
Chronic Disease

Pembrolizumab and chemotherapy combination improves survival in advanced pleural mesothelioma

January 24, 2024
Dacomitinib may be effective in EGFR-associated lung cancer
Oncology

Abemaciclib linked to disease control in patients with p16ink4A-negative mesothelioma

March 27, 2022
Next Post
Nivolumab may be effective in platinum-resistant ovarian cancer

Active monitoring compared to maintenance capecitabine is a viable alternative for stable metastatic colorectal cancer

COVID-19: Over 1,000 test positive on the first phase of rapid testing

Insulin costs rose exponentially, regardless of formulation or patent

Insulin management in hospitalized patients with diabetes mellitus on high-dose glucocorticoids

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Living in a marginalized neighbourhood is associated with worse outcomes in patients with myocardial infarction
  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.